tbuckley/cabot-search huggingface dataset:
Abstract 051: Growth Plasticity Of The Prenatal Murine Heart Depends On Amino Acid Availability
Authors: Maria Hennig, Maja K Dziegelewska, Manuela Magarin, Ludwig Thierfelder, Jörg-Detlef Drenckhahn
Journal: Circulation Research (2013)

Intrauterine development influences the susceptibility to cardiovascular disease in adulthood, although the underlying molecular mechanisms are vastly unknown. We have recently shown that the prenatal mouse heart has an impressive regenerative capacity in response to tissue mosaicism for mitochondrial dysfunction caused by a heart specific knockout of holocytochrome c synthase (Hccs) - an X-linked gene required for mitochondrial respiration. In heterozygous Hccs knockout (Hccs+/-) embryos, hyperproliferation of healthy cardiomyocytes compensates for the functional loss of 50% of Hccs deficient cells, ensuring formation of a normally contracting heart at birth. In order to uncover molecular mechanisms enabling compensatory growth of the prenatal myocardium, we performed microarray RNA expression analyses on neonatal Hccs+/- and control hearts. These data revealed numerous genes involved in amino acid metabolism and protein homeostasis being differentially expressed in the neonatal Hccs+/- myocardium. We, therefore, hypothesized that amino acid availability is crucial for compensatory growth of Hccs+/- hearts to build a regularly sized organ and allow normal postnatal function. Thus, we studied the effects of in utero amino acid restriction on growth and development of Hccs+/- hearts by feeding dams a low protein diet (LPD) throughout pregnancy and keeping the offspring on LPD until adulthood. On standard protein diet heart weight to body weight ratio of Hccs+/- mice (n=26) born at gestational age 20.5 dpc does not differ compared to littermate controls (n=21). In contrast, Hccs+/- offspring on LPD (n=20) were found to have a significantly reduced heart weight to body weight ratio compared to control animals (n=19) at postnatal day 1. Importantly, cardiomyocyte size and proliferation were unaffected in neonatal Hccs+/- hearts on LPD, suggesting that amino acid restriction rather inhibits prenatal cardiac growth. This was in line with normal heart size and function in adult LPD Hccs+/- mice, confirming normal postnatal development. In conclusion, metabolic adaptations regulating amino acid availability might be required for growth plasticity of the fetal heart to prevent postnatal dysfunction after impaired intrauterine development.
Human adipose derived stem cells are superior to human osteoblasts (HOB) in bone tissue engineering on a collagen-fibroin-ELR blend
Authors: Esen Sayin, Rosti Hama Rashid, José Carlos Rodríguez-Cabello, Ahmed Elsheikh, Erkan Türker Baran, Vasif Hasirci
Journal: Bioactive Materials (2017)

The ultrastructure of the bone provides a unique mechanical strength against compressive, torsional and tensional stresses. An elastin-like recombinamer (ELR) with a nucleation sequence for hydroxyapatite was incorporated into films prepared from a collagen – silk fibroin blend carrying microchannel patterns to stimulate anisotropic osteogenesis. SEM and fluorescence microscopy showed the alignment of adipose-derived stem cells (ADSCs) and the human osteoblasts (HOBs) on the ridges and in the grooves of microchannel patterned collagen-fibroin-ELR blend films. The Young's modulus and the ultimate tensile strength (UTS) of untreated films were 0.58 ± 0.13 MPa and 0.18 ± 0.05 MPa, respectively. After 28 days of cell culture, ADSC seeded film had a Young's modulus of 1.21 ± 0.42 MPa and UTS of 0.32 ± 0.15 MPa which were about 3 fold higher than HOB seeded films. The difference in Young's modulus was statistically significant (p: 0.02). ADSCs attached, proliferated and mineralized better than the HOBs. In the light of these results, ADSCs served as a better cell source than HOBs for bone tissue engineering of collagen-fibroin-ELR based constructs used in this study. We have thus shown the enhancement in the tensile mechanical properties of the bone tissue engineered scaffolds by using ADSCs.
Blood endothelial cells: utility from ambiguity
Authors: Robert P. Hebbel
Journal: Journal of Clinical Investigation (2017)

In the mid-1990s, my research group began to devise a method to establish endothelial cell cultures from human peripheral blood, with an ultimate goal of examining interindividual heterogeneity of endothelial biology. The initial work, published in the JCI in 2000, described the method enabling successful attainment of blood outgrowth endothelial cells (BOEC). Truly endothelial, BOEC are progeny of a transplantable cell that originates in bone marrow, a putative endothelial progenitor. Our subsequent experimental work focused upon practical applications of BOEC: their use for gene therapy, tissue engineering, assessment of mutant gene effect, and discovery of heterogeneity in endothelial biology.
p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma
Authors: Mariateresa Fulciniti, Joaquin Martinez Lopez, William Senapedis, Stefania Oliva, Raphaël Szalat, Mehmet K. Samur, Rao H Prabhala, Kenneth C. Anderson, Nikhil C Munshi
Journal: Blood (2016)
Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer
Authors: Jill J.J. Geenen, Jan H.M. Schellens
Journal: Clinical Cancer Research (2017)

Wee1 is a protein kinase that regulates the G2 checkpoint and prevents entry into mitosis in response to DNA damage. Cyclin-dependent kinases (CDK) are a family of 14 serine/threonine protein kinases that coordinate the progression through the cell cycle. The Cdc2/cyclin B complex controls the progression from G2 into mitosis. There are two mechanisms by which the G2 checkpoint is initiated in response to DNA damage: phosphorylation of Cdc25c by CHK1 and of the Wee1 kinase, which phosphorylates Cdc2. Blockade at the G2 checkpoint is especially important for p53-mutant cells because these tumors mainly rely on DNA repair at the G2 checkpoint. AZD1775 (formerly MK-1775) is a small-molecule, pyrazol-pyrimidine derivative and potent and ATP-competitive specific inhibitor of the Wee1 kinase. Several preclinical and clinical studies demonstrated encouraging antitumor effects with manageable side effects of the combination of Wee1 inhibition and DNA-damaging agents. Promising combination schedules are being investigated at the moment, for example, combining PARP inhibition and Wee1 inhibition. Also, a weekly schedule with carboplatin and AZD1775 warrants investigation aimed at further improving the antitumor effect. Clin Cancer Res; 23(16); 4540-4. ©2017 AACR.
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
Authors: A Dispenzieri, C Tong, B LaPlant, M Q Lacy, K Laumann, D Dingli, Y Zhou, M J Federspiel, M A Gertz, S Hayman, F Buadi, M O'Connor, V J Lowe, K-W Peng, S J Russell
Journal: Leukemia (2017)
IMPROVED CLINICAL OUTCOME IN ATRIAL FIBRILLATION PATIENTS UNDERGOING PULMONARY VEIN ANTRUM ISOLATION USING OBJECTIVE SOFTWARE-BASED DEMARCATION OF ABLATION LESIONS, VISITAG™
Authors: Pouria Alipour, Yaariv Khaykin, Lauren Liu, Elaine Novik, Meysam Pirbaglou, Paul Ritvo, Alfredo Pantano, Atul Verma
Journal: Journal of the American College of Cardiology (2016)
Physical Activity, Obesity, and Subclinical Myocardial Damage
Authors: Roberta Florido, Chiadi E. Ndumele, Lucia Kwak, Yuanjie Pang, Kunihiro Matsushita, Jennifer A. Schrack, Mariana Lazo, Vijay Nambi, Roger S. Blumenthal, Aaron R. Folsom, Josef Coresh, Christie M. Ballantyne, Elizabeth Selvin
Journal: JACC Heart Failure (2017)
Allostasis and the Epigenetics of Brain and Body Health Over the Life Course
Authors: Bruce S. McEwen
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
P14.08 Prognostic factors for the time from primary diagnosis to development of brain metastases in patients with breast cancer in Indonesia
Authors: R. A. Hendrojogi, S. A. Wilopo, T. Aryandono, S. Wibowo
Journal: Neuro-Oncology (2017)

BACKGROUND: Brain metastasis from the breast cancer (BMBC) is the biggest challenge for neuro-oncologist since limited of availabilities on ­management and treatment for breast cancer (BC) patients. The problem is whether the identification of prognostic factors and the construction of prognostic model can help to screen and clinical management for BMBC patient? Goal and Objectives: The goal of this research to improve survival of BC patient by identifying prognostic factors for time of development of BMBC in Indonesian women. The objectives of this study: a) to describe epidemiology, management and prognostic factors of BMBC; b) identification main prognostic for BMBC and construct prognostic models for improving effectiveness and efficiencies of clinical management. Study Design: is a prospective cohort study. SETTINGS: This study was conducted on BC patients admitted to Dharmais National Cancer Hospital, Jakarta, Indonesia. Samples: followed-up prospectively for 516 BC without BMBC ages 25-75 who were attending hospital from January 1, 2013 to December 31, 2013. The cut of date of follow-up was July 31, 2015. We recorded event of BMBC, death, or lost to follow-up. Prognostic Factors: In addition to tumor subtype, the study collected data on surgery, chemotherapy, hormonal therapy and radiation to primary tumor and other risk factors, such as tumor subtype, metastases to extra cranial, age, stadium and tumor grade. Study Outcomes: The dependent variable of this study is the time since diagnosed BC until BMBC event. Risk factors identification used Cox’s regression to obtain relative risk (RR) estimates. Results: This is a first report on cumulative incidence of BMBC among BC patients using prospective design in Indonesia where the incidence of BMBC is reported as 15-20%. According to epidemiological profiles, BMBC are commonly found among younger women (age below 40 years), high school graduate or higher, and the hospital payment using insurance. A tumor subtype of Luminal A has higher percentage (48%) where HER2 subtype is lowest (11.7%) in Indonesia. This study found risks of having BMBC as follows: age at the time of BC diagnosed, tumor subtype (tests ER, PR and HER2 receptor), grade, stadium and metastases extracranial (lung, liver, bone). The best prognostic model (R2 >15%) for the time to the development of BMBC using those factors has RR 2.6 to 8.8 which are statistically significant. CONCLUSION AND RECOMMENDATION: Breast cancer patient can be screened using prognostic factors at the earlier stage of care. We recommend to screen and manage BMBC patient by considering age of women, tumor subtype (tests ER, PR and HER2 receptor), grade, stadium and metastases extracranial (lung, liver, bone).
CHANGES IN THE HIP IN YOUTH HOCKEY PLAYERS OVER 5 SEASONS
Authors: Karen Briggs, Marc Philippon, Shannen McNamara, Charles Ho
Journal: British Journal of Sports Medicine (2017)

Background It has been reported that relative to other sports participants, ice hockey players suffer from cam femoroacetabular impingement (FAI) in higher numbers. Alpha angles have been reported to increase with the likelihood of symptomatic FAI. It is unclear how alpha angle and other factors related to FAI change over early childhood years. Objective Track youth hockey players over 5 years and determine if factors associated with FAI increased as they aged and increased skating time. Design Screening. Setting Youth club. Patients (or Participants) 16 asymptomatic youth ice hockey players. All players started in the peewee(ages 10 to 12) division and moved up in divisions over the 3 years. Interventions (or Assessment of Risk Factors) Clinical hip examination consisting of the FABER test, impingement testing, and measurement of hip internal rotation. An MRI was taken and the hip alpha angle was measured and labral tears were documented. Main Outcome Measurements Alpha angle and labral tear on MRI Results These youth hockey players played an average of 42 weeks/year Players had significantly increased alpha angle by year 3 of screening. The average alpha angle at year 1 was 56(range 45 to 63), year 2 was 59 (range 52 to 68), year 3 was 75 (range 64 to 88), year 4 was 75 and year 5 was 78. By year 5, 14/16 had asymptomatic labral tears. There were no significant changes in internal rotation over the 5 years. There was a trend toward decreased internal rotation in goalies. Conclusions Young ice hockey players show increasing alpha angles and development of asymptomatic labral tears. Stresses inherent to ice hockey likely enhance the development of a bony overgrowth on the femoral neck contributing to cam FAI.
P08.31 Periostin is expressed by pericytes and promotes angiogenesis under the control of glial tumor cells
Authors: J. M. Kros, K. Huizer, C. Zhu, C. Cheng, D. A. M. Mustafa
Journal: Neuro-Oncology (2017)

In a previous study we sought proteins that are specifically expressed in the context of glioma angiogenesis. To that aim, we compared microdissected GBM vessels with normal brain vessels and vessels of proliferating endometrium representing physiological angiogenesis. Among the proteins that were overexpressed in GBMs we most prominently found periostin. In this study we explored the expression of periostin at the protein and RNA level and sought its cellular source in the gliomas. In functional studies using gene silencing in cell cultures we studied the effects of periostin on angiogenesis and explored its regulators. We found that periostin is mainly expressed by (PDGFR+) pericytes and that these cells usually carry glioma stem cell characteristics. Co-culture experiments revealed that conditioned medium of the glioma cell line U87 increased the periostin expression by pericytes. Silencing of POSTN in pericytes in the co-cultures with endothelial cells resulted in reduction of the formation, length and junctions of the vascular tubules. We conclude that the expression of periostin is a crucial element of glioma angiogenesis. Its expression by pericytes is stimulated by the presence of glial tumor cells. The data open new clues for the development of new anti-angiogenic strategies for gliomas.
Bariatric Surgery Has Durable Effects in Controlling Diabetes
Authors: Anita Slomski
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience
Authors: Selina J Chavda, Paul Michael Maciocia, Pavlina Mesiri, Nicholas Counsell, Jaimal Kothari, Antonia Bird, Ciaran Mariner, Anastasia Chew, Katherine Clesham, Sally Moore, Laura Percy, Ali Rismani, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong
Journal: Blood (2016)
Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part VII. Neonatal resuscitation
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P168: Activated Protein C Inhibits the Development of Myocardial Fibrosis
Authors: Mryanda J Sopel, Tanya L Myers, Timothy D Lee, Robert S Liwski, Jean-Francois Legare
Journal: Circulation Research (2011)

Background: Activated Protein C (aPC) is a naturally produced circulating anticoagulant with anti-inflammatory and cytoprotective properties proposed to have beneficial effects on the myocardium. Myocardial fibrosis is a pathophysiologic process evident in many cardiovascular diseases and is believed to directly contribute to eventual organ failure. Using a well-described model of myocardial fibrosis after Angiotensin II (AngII) infusion our aim was to investigate the novel therapeutic function of aPC in the development of fibrosis. Methods: C57Bl/6 mice were continuously infused with AngII (2.0 μ g/kg/min), AngII and aPC (0.4 μ g/kg/min), or saline for a 3d period. Hearts were harvested and processed for analysis. Cellular infiltration and collagen deposition were analyzed using histologic staining. Cellular apoptosis was assessed using a TUNEL assay. Quantitative RT-PCR was used to assess transcript levels of molecular mediators. Results: Infusion of AngII for 3d resulted in multifocal areas of myocardial cellular infiltration associated with significant collagen deposition compared to saline control animals (p≤0.01). The addition of aPC with AngII infusion inhibited this fibrotic response. Co-administration with aPC also inhibited the upregulation of the pro-fibrotic cytokine CTGF expression seen in AngII infused animals (p≤0.01). Apoptosis was also significantly inhibited when aPC was co-administered based on a decrease of in TUNEL positive cells and an increase expression ration of BCL/BAX suggesting an anti-apoptotic effect (p≤0.01), Furthermore, aPC also inhibited the up-regulation of the cell adhesion molecule p-selectin seen in AngII infused animals (p≤0.01). Conclusion: The co-administration of aPC in a model of myocardial fibrosis was able to abrogate completely the fibrotic response. The mechanism of action of aPC appears to be a decreased cellular adhesion molecule expression in the myocardium leading to decreased cellular infiltration and enhanced cellular survival. This data suggests that aPC has the potential as a therapeutic agent in cardiovascular diseases.
Plain cigarette packs may cut number of smokers, evidence review finds
Authors: Jacqui Wise
Journal: BMJ (2017)

Standardised cigarette packaging may reduce the number of people who smoke, a Cochrane review has concluded.1

Standardised packaging for all tobacco packs comes into full effect in the UK next month. The rules require packs to be produced in a drab dark brown, with only minimal text including the manufacturer’s brand name in size 14 font.2

Australia was the first country to implement standardised tobacco packaging, from October 2012. France implemented it on 1 January 2017, and several other countries are planning to follow suit.

The Cochrane researchers found 51 studies that looked at standardised packaging. However, …
P09.50 Phase I trial of temozolomide plus bevacizumab for newly diagnosed high-grade gliomas in the elderly: Interim report
Authors: M. Kono, Y. Arakawa, Y. Mineharu, F. Ohka, M. Kinoshita, S. Nakae, K. Miyashita, T. Iuchi, Y. Hirose, A. Natsume, M. Nakada, H. Sasaki
Journal: Neuro-Oncology (2017)

Introduction: Although more than 10% of glioblastomas arises in the elderly over 75 y/o, treatment options for these patients are very limited. Randomized clinical trials suggested that bevacizumab (BEV) administration is associated with favorable event-free survival and improvement in the patient performance status (PS). Materials and Methods: We are conducting a Phase I study to evaluate the safety of temozolomide (TMZ) plus BEV in patients with high-grade glioma (HGG) over 75 y/o. Additional eligibility criteria included PS at least 3. Radiological diagnosis of HGG without biopsy was admitted. Patients with history of cardiovascular events, cerebral infarction, deep vein thrombosis, or pulmonary embolism within 6 months (M) were excluded. TMZ was administered between days 1 (2) and 5 (6) in 28-day cycle at a dose of 150-200 mg/m2. BEV was administered on days 1 and 15 in the first 28-day cycle, and on day 1 in the subsequent cycles at a dose of 10 mg/kg. The trial was approved by the Institutional Review Board at all participating institutions. Results: 10 patients (age 75 - 90, median 80.5 y/o) were enrolled, and median follow-up is 11M (3 - 20M) as of November, 2016. Grade 4 liver dysfunction occurred in a PS 3, 90 y/o patient to whom the first course of TMZ/BEV was mistakenly administered despite increased aminotransferases above the treatment initiation criteria. Another adverse events possibly related to the treatment protocol included proteinuria (grade 3), tumor hemorrhage (grade 3, 2 cases), and perianal abscess (grade 2). Conclusions: TMZ plus BEV seems safe for the patients with HGG over 75 y/o, and may be among treatment options.